

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Jul 2019 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Aflibercept	Eylea	Eye	Approved	
2	Bictegravir/emtricitabine/tenofovir alafenamide fumarate	Biktarvy	Infections	Approved	
3	Brentuximab Vedotin	Adcetris	Malignant disease and immunosuppression	Pending	Pending further information
4	Brigatinib	Alunbrig	Malignant disease and immunosuppression	Approved	
5	Ciclosporin eye drops	Ikervis	Eye	Approved	
6	Emicizumab	Hemlibra	Cardiovascular system	Pending	Pending further information
7	Insulin degludec / insulin aspart	Ryzodeg FlexTouch	Endocrine system	Approved	
8	Insulin glargine / Lixisenatide	Soliqua	Endocrine system	Approved	
9	Lenvatinib	Lenvima	Malignant disease and immunosuppression	Approved	
10	Midostaurin	Rydapt	Malignant disease and immunosuppression	Approved	
11	Olaparib	Lynparza	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
12	Osimertinib	Tagrisso	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
13	Oxycodone	OxyContin / OxyNorm	Central nervous system	Rejected	Alternative(s) available in HADF with comparable benefits
14	Pertuzumab	Perjeta	Malignant disease and immunosuppression	Pending	Pending further information
15	Racecadotril	Hidrasec	Gastro-intestinal system	Pending	Pending further information
16	Ribociclib	Kisqali	Malignant disease and immunosuppression	Approved	
17	Riociguat	Adempas	Cardiovascular system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
18	Rifapentine	Priftin	Infections	Pending	Pending further information
19	Ruxolitinib	Jakavi	Malignant disease and immunosuppression	Approved	

20	Selexipag	Uptravi	Cardiovascular system	Rejected	Insufficient evidence of long-term clinical outcome benefits
21	Tolvaptan	Jinarc	Endocrine system	Pending	Pending further information

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.